{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:04:49Z","timestamp":1787025889436,"version":"build-2736575974"},"reference-count":30,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2022,9,13]]},"abstract":"<jats:p>Background: Recent advances occurred in the field of Alzheimer\u2019s disease (AD) biomarkers and the introduction of a research framework grounded on a biomarker-based definition of AD might have fostered an increased clinical use of AD biomarkers. For this reason, an up-to-date depiction of the clinical use of AD biomarkers is needed. Objective: To investigate the clinical use of the main AD biomarkers in patients with mild cognitive impairment (MCI) by examining the beliefs and preferences of professionals (clinicians and biomarker experts) of the European Alzheimer\u2019s Disease Consortium (EADC). Methods: 150 professionals filled in an online survey from May to September 2020. The investigated biomarkers were medial temporal lobe atrophy score (MTA) on structural MRI, typical AD (i.e., temporoparietal and posterior cingulate) hypometabolism on FDG-PET, CSF (A\u03b242, p-tau, t-tau), amyloid-PET and tau-PET. Results: The frequency of responders reporting a frequent-to-constant use of MTA (77%) is higher than that of those reporting a frequent-to-constant use of the other AD biomarkers (i.e., CSF: 45%, p\u200a=\u200a0.014; FDG-PET: 32%, p\u200a&lt;\u200a0.001; amyloid-PET: 8%, p\u200a&lt;\u200a0.001; and tau-PET: 2%, p\u200a&lt;\u200a0.001). CSF is considered the most valuable biomarker in terms of additional diagnostic value, followed by amyloid-PET, tau-PET, and typical AD hypometabolism on FDG-PET. Conclusion: AD biomarkers are widely used across European memory clinics with a clinical research background for the diagnosis of MCI. Overall, we observed that CSF is currently considered as the most useful biomarker, followed by amyloid-PET.<\/jats:p>","DOI":"10.3233\/jad-220333","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T13:30:26Z","timestamp":1658842226000},"page":"535-551","source":"Crossref","is-referenced-by-count":16,"title":["The Clinical Use of Alzheimer\u2019s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer\u2019s Disease Consortium Survey"],"prefix":"10.1177","volume":"89","author":[{"given":"Camilla","family":"Caprioglio","sequence":"first","affiliation":[{"name":"Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland"},{"name":"Geneva Memory Center, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the European Alzheimer\u2019s Disease Consortium (EADC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland"},{"name":"Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Hospital and Medical Faculty, University of Cologne, Cologne, Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Fr\u00f6lich","sequence":"additional","affiliation":[{"name":"Department of Geriatric Psychiatry, Central Institute for Mental Health, University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Allali","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland"},{"name":"Department of Neurology, Division of Cognitive & Motor Aging, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Assal","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland"},{"name":"Geneva Memory Center, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Altomare","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland"},{"name":"Geneva Memory Center, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-220333_ref1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220333_ref2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220333_ref3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00259-019-04466-6","article-title":"Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer\u2019s disease","volume":"47","author":"Ramusino","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-220333_ref4","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1007\/s00259-021-05246-x","article-title":"Diagnostic value of amyloid-PET and tau-PET: A head-to-head comparison","volume":"48","author":"Altomare","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-220333_ref5","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2967\/jnumed.116.185017","article-title":"Clinical use and utility of amyloid imaging","volume":"58","author":"Barthel","year":"2017","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-220333_ref6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","article-title":"Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease","volume":"11","author":"Blennow","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220333_ref7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220333_ref8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/gps.5427","article-title":"Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer\u2019s disease consortium survey","volume":"36","author":"Frederiksen","year":"2021","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-220333_ref9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","article-title":"Practice guideline update summary: Mild cognitive impairment report of theguideline development, dissemination, and implementation","volume":"90","author":"Petersen","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JAD-220333_ref10","unstructured":"Aducanumab (marketed as Aduhelm) Information, Last updated 2021, Accessed on 2022."},{"key":"10.3233\/JAD-220333_ref11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220333_ref12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2967\/jnumed.120.244061","article-title":"One-stop shop: 18 F-Flortaucipir PET differentiates amyloid-positive and -negative forms of neurodegenerative diseases","volume":"62","author":"Hammes","year":"2021","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-220333_ref13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-220333_ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000439255","article-title":"Do beliefs about the pathogenetic role of amyloid affect the interpretation of amyloid PET in the clinic?","volume":"16","author":"Boccardi","year":"2016","journal-title":"Neurodegener Dis"},{"key":"10.3233\/JAD-220333_ref15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jalz.2014.06.006","article-title":"The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey","volume":"11","author":"Bocchetta","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220333_ref16","doi-asserted-by":"crossref","first-page":"E1635","DOI":"10.1212\/WNL.0000000000008361","article-title":"Applying the ATN scheme in a memory clinic population: The ABIDE project","volume":"93","author":"Altomare","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JAD-220333_ref17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220333_ref18","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1007\/s00415-019-09441-7","article-title":"Prognostic value of Alzheimer\u2019s biomarkers in mild cognitive impairment: The effect of age at onset","volume":"266","author":"Altomare","year":"2019","journal-title":"J Neurol"},{"key":"10.3233\/JAD-220333_ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-019-0525-9","article-title":"Use of mild cognitive impairment and prodromal AD\/MCI due to AD in clinical care: A European survey","volume":"11","author":"Bertens","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220333_ref20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/JAD-130098","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808","volume":"38","author":"Chien","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220333_ref21","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2018.12917","article-title":"Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders","volume":"320","author":"Ossenkoppele","year":"2018","journal-title":"JAMA"},{"key":"10.3233\/JAD-220333_ref22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jalz.2015.08.003","article-title":"Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study","volume":"12","author":"Duits","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220333_ref23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","article-title":"The probabilistic model of Alzheimer disease: The amyloid hypothesis revised","volume":"23","author":"Frisoni","year":"2022","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-220333_ref24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41582-020-00416-1","article-title":"Genetic testing in dementia \u2014 utility and clinical strategies","volume":"17","author":"Koriath","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-220333_ref25","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","article-title":"Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype","volume":"15","author":"Vermunt","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220333_ref26","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1212\/NXG.0000000000000512","article-title":"Late-onset vs nonmendelian early-onset Alzheimer disease","volume":"6","author":"Reitz","year":"2020","journal-title":"Neurol Genet"},{"key":"10.3233\/JAD-220333_ref27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/GIM.0b013e31821d69b8","article-title":"Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors","volume":"13","author":"Goldman","year":"2011","journal-title":"Genet Med"},{"key":"10.3233\/JAD-220333_ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2006.01605.x","article-title":"Recommendations for the diagnosis and management of Alzheimer\u2019s disease and other disorders associated with dementia: EFNS guideline","volume":"14","author":"Waldemar","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-220333_ref29","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/ene.13945","article-title":"Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment","volume":"26","author":"Falg\u00e0s","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-220333_ref30","first-page":"221","article-title":"Is a large-scale screening for Alzheimer\u2019s disease possible? Yes, in a few years","volume":"6","author":"Ribaldi","year":"2019","journal-title":"J Prev Alzheimers Dis"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-220333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:06:49Z","timestamp":1777370809000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-220333"}},"subtitle":[],"editor":[{"given":"Stefano","family":"Tamburin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":30,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-220333","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]}}}